Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Vivani Medical Inc. (VANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VANI (1-star) is a SELL. SELL since 2 days. Profits (11.50%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.11% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.24M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 3.25 | 52 Weeks Range 0.91 - 1.80 | Updated Date 08/15/2025 |
52 Weeks Range 0.91 - 1.80 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date 2025-08-19 | When - | Estimate -0.095 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.42% | Return on Equity (TTM) -177.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87061756 | Price to Sales(TTM) - |
Enterprise Value 87061756 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.93 | Shares Outstanding 59243900 | Shares Floating 30972712 |
Shares Outstanding 59243900 | Shares Floating 30972712 | ||
Percent Insiders 49.04 | Percent Institutions 8.04 |
Upturn AI SWOT
Vivani Medical Inc.
Company Overview
History and Background
Vivani Medical Inc. (formerly Second Sight Medical Products) was founded focusing on innovative implantable medical devices. Their initial focus was on restoring sight to the blind. Pivoting, they now focus on long-term drug delivery technologies.
Core Business Areas
- Drug Delivery Systems: Development of miniaturized, long-term implantable drug delivery systems designed to address chronic diseases.
Leadership and Structure
The leadership team consists of medical device and pharmaceutical executives. Organizational structure is typical of a development-stage medical device company.
Top Products and Market Share
Key Offerings
- NCT-250: A miniature, subdermal implant for continuous, six-month delivery of exenatide for the treatment of type 2 diabetes and potentially weight management. NCT-250 is in Phase 2 trials. Market share is currently 0%. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY), and other established diabetes drug manufacturers.
- NCT-250 Revenue: 0
- NCT-250 Users: 0
Market Dynamics
Industry Overview
The drug delivery systems market is experiencing growth driven by the need for improved patient compliance, targeted drug delivery, and reduced side effects. The diabetes treatment market is substantial and competitive.
Positioning
Vivani Medical is positioned as an innovator in long-term drug delivery, seeking to differentiate itself through its miniaturized implant technology.
Total Addressable Market (TAM)
The global diabetes treatment market is estimated at hundreds of billions of dollars annually. Vivani Medical is positioned to capture a share of this TAM with its innovative delivery method, aiming to improve patient adherence and outcomes.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology
- Potential for improved patient compliance
- Focus on chronic diseases
- Experienced leadership team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Lack of commercialized products
- Small Market Cap
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Acquisition by a larger company
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- NVO
- LLY
- ITCI
- ALNY
Competitive Landscape
Vivani Medical faces intense competition from established pharmaceutical giants with significantly greater resources. Its advantage lies in its novel delivery technology and potential for improved patient adherence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company is focused on development.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analysts have projected potential for substantial revenue growth if NCT-250 is approved.
Recent Initiatives: Focus on NCT-250 Phase 2 trials and exploring partnerships with larger pharmaceutical companies.
Summary
Vivani Medical is a development-stage company with an innovative drug delivery technology targeting the treatment of Type 2 Diabetes and Obesity. The company's success hinges on the outcome of its clinical trials. While the technology shows promise, financial resources are limited, and the company faces fierce competition from established players in the pharmaceutical industry. Investors should carefully evaluate the risks associated with investing in a clinical-stage company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vivani Medical Inc.
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2014-11-19 | Co-Founder, CEO & Director Dr. Adam Mendelsohn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://www.vivani.com |
Full time employees 37 | Website https://www.vivani.com | ||
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.